Aug 2, 2018
64 Views

Recreational Genetics or Research Enterprise? Cloudy Consent Issues Arising from Direct-to-Consumer Genetic Testing

Written by



By Valerie Gutmann Koch 23andMe announced its $300 million partnership with GlaxoSmithKline late last month, a move that will allow the drug behemoth to develop drugs based on “deidentified” DNA and other information collected from the direct-to-consumer (DTC) genetic testing … Continue reading



Source link

Article Categories:
Health Law Policy

Leave a Comment

Your email address will not be published. Required fields are marked *